167 related articles for article (PubMed ID: 21367750)
1. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
Zauli G; Voltan R; di Iasio MG; Bosco R; Melloni E; Sana ME; Secchiero P
Clin Cancer Res; 2011 May; 17(9):2712-24. PubMed ID: 21367750
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
[TBL] [Abstract][Full Text] [Related]
4. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
[TBL] [Abstract][Full Text] [Related]
5. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
di Iasio MG; Norcio A; Melloni E; Zauli G
Invest New Drugs; 2012 Dec; 30(6):2403-6. PubMed ID: 22238073
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
Voltan R; Secchiero P; Corallini F; Zauli G
Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
[TBL] [Abstract][Full Text] [Related]
7. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
[TBL] [Abstract][Full Text] [Related]
9. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
10. Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.
Celeghini C; Voltan R; Rimondi E; Gattei V; Zauli G
Invest New Drugs; 2011 Apr; 29(2):392-5. PubMed ID: 20130960
[TBL] [Abstract][Full Text] [Related]
11. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-34a promotes MICB expression in hepatocytes.
Zhou MT; Zhao C; Chen X; Zhang HC; Li G; Lou H; Huang WJ; Wei LJ; Li DW; Wu X; Zhang ZC; Liu H; Ou R; Yang WJ; Hu S; Xu Y; Tang KF
Carcinogenesis; 2018 Dec; 39(12):1477-1487. PubMed ID: 30256916
[TBL] [Abstract][Full Text] [Related]
13. The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis.
Kiyonari S; Iimori M; Matsuoka K; Watanabe S; Morikawa-Ichinose T; Miura D; Niimi S; Saeki H; Tokunaga E; Oki E; Morita M; Kadomatsu K; Maehara Y; Kitao H
Mol Cancer Ther; 2015 Oct; 14(10):2332-42. PubMed ID: 26208523
[TBL] [Abstract][Full Text] [Related]
14. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
15. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
Kumamoto K; Spillare EA; Fujita K; Horikawa I; Yamashita T; Appella E; Nagashima M; Takenoshita S; Yokota J; Harris CC
Cancer Res; 2008 May; 68(9):3193-203. PubMed ID: 18451145
[TBL] [Abstract][Full Text] [Related]
16. Co-regulation of B-Myb expression by E2F1 and EGF receptor.
Hanada N; Lo HW; Day CP; Pan Y; Nakajima Y; Hung MC
Mol Carcinog; 2006 Jan; 45(1):10-7. PubMed ID: 16299810
[TBL] [Abstract][Full Text] [Related]
17. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
[TBL] [Abstract][Full Text] [Related]
18. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.
Secchiero P; Rimondi E; di Iasio MG; Voltan R; Gonelli A; Zauli G
J Cell Physiol; 2012 May; 227(5):1829-37. PubMed ID: 21732354
[TBL] [Abstract][Full Text] [Related]
19. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Rizzo M; Mariani L; Cavallini S; Simili M; Rainaldi G
Nucleic Acid Ther; 2012 Aug; 22(4):283-8. PubMed ID: 22830357
[TBL] [Abstract][Full Text] [Related]
20. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.
di Iasio MG; Zauli G
Invest New Drugs; 2013 Apr; 31(2):458-60. PubMed ID: 23054209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
